March 18, 2010

Silverstrand Investments v. Amag Pharmaceuticals, Inc. et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. April 09, 2014

    AMAG Pharma Fails To Shirk Drug-Risks Investor Suit

    A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment Feraheme, ruling Monday that the suit could continue in light of the First Circuit's reviving the case.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!